Abstract
Anti-tobacco advocates are celebrating after tobacco company Philip Morris International was finally ejected from a collaboration producing the only COVID-19 vaccine to be manufactured in Canada—Covifenz. The Montreal-based COVID-19 vaccine developer Medicago announced, in December, 2022, that majority shareholder Mitsubishi Tanabe Pharma had removed Philip Morris as a secondary investor, by buying out all of the tobacco company's shares. The problems did not end there for Medicago. Beset by manufacturing and other organisational problems, and having not delivered a single dose commercially in Canada or beyond, Mitsubushi announced, as The Lancet Respiratory Medicine went to press, that Medicago was being closed down and the vaccine project discontinued.”
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
